How long to take ursodiol after gastric sleeve surgery is a common question for patients navigating post-operative care. Ursodeoxycholic acid (UDCA) — prescribed to reduce the risk of gallstone formation during rapid weight loss — is a standard part of many NHS bariatric care pathways following sleeve gastrectomy. The duration of treatment varies between individuals and clinical centres, but most patients are advised to take it for around six months. This article explains why UDCA is prescribed, how long you are likely to need it, how to take it correctly, and when to speak to your surgical team about stopping.

Why Ursodeoxycholic Acid Is Prescribed After Gastric Sleeve Surgery

UDCA is prescribed after gastric sleeve surgery to prevent cholesterol gallstones, which form when rapid weight loss causes the liver to secrete excess cholesterol into bile. Without prophylaxis, a significant proportion of patients may develop gallstones within the first year.

Ursodeoxycholic acid (UDCA) — known as ursodiol in the United States — is a naturally occurring bile acid commonly prescribed following bariatric procedures, including gastric sleeve (sleeve gastrectomy) surgery. Its primary purpose in this context is to reduce the risk of developing gallstones during the period of rapid weight loss that follows the operation.

After gastric sleeve surgery, the body undergoes significant metabolic changes. Rapid weight loss causes the liver to secrete excess cholesterol into bile, which can lead to the formation of cholesterol gallstones — a well-documented complication of bariatric surgery. Evidence suggests that without preventive treatment, a substantial proportion of patients (often cited in the range of 20–40%) may develop gallstones within the first year following surgery, though rates of symptomatic gallstone events are lower. The risk is greatest during the phase of most rapid weight loss.

UDCA works by:

• Reducing cholesterol saturation in bile, making it less likely to crystallise and form stones

• Improving bile flow and reducing the biliary stasis that contributes to stone formation

• Dissolving small cholesterol crystals before they develop into symptomatic gallstones

In the UK, ursodeoxycholic acid is licensed for use in gallstone-related conditions and is available on prescription. Its use specifically as prophylaxis after bariatric surgery is an off-label application in the UK; however, it is widely supported by clinical evidence and used within many NHS bariatric care pathways in accordance with local Trust protocols and guidance from the British Obesity and Metabolic Surgery Society (BOMSS). UDCA prophylaxis is not required if you have already had your gallbladder removed (cholecystectomy) prior to or during your bariatric procedure. Your surgical team will assess your individual risk factors — including your rate of weight loss, pre-existing biliary conditions, and overall health — before prescribing it.

How Long You Will Typically Need to Take Ursodeoxycholic Acid

Most patients take UDCA for six months after gastric sleeve surgery, covering the period of most rapid weight loss. Higher-risk patients may be advised to continue for up to twelve months at their bariatric team's discretion.

The duration of UDCA treatment after gastric sleeve surgery is not universally standardised, and guidance can vary between NHS Trusts and individual bariatric centres. However, the most commonly recommended treatment period is six months following surgery. This timeframe corresponds to the phase of most rapid weight loss, during which the risk of gallstone formation is at its highest.

Some bariatric programmes extend the prescription to twelve months, particularly for patients in whom active, rapid weight loss continues beyond the initial six-month period, those with a higher body mass index (BMI) at the time of surgery, or those with other risk factors such as a history of biliary symptoms or a family history of gallstones. In a smaller number of cases, treatment may be continued beyond twelve months if clinically indicated. Note that the rationale for extending treatment is linked to ongoing rapid or prolonged active weight loss — not to slower weight loss, which carries a lower risk.

Key points regarding treatment duration:

• Most patients: 6 months post-surgery, per local bariatric protocol

• Higher-risk patients: Up to 12 months, at the discretion of the surgical or bariatric team

• This is an off-label preventive use in the UK, guided by local NHS Trust and BOMSS protocols

• Imaging: Routine ultrasound surveillance of the gallbladder is not standard practice in asymptomatic patients; however, imaging may be arranged if you develop biliary symptoms or if there is a specific clinical indication

It is important not to stop UDCA earlier than advised without consulting your surgical team, as doing so during the period of active rapid weight loss may leave you unprotected against gallstone formation. Equally, there is generally no clinical benefit to continuing the medication indefinitely once the period of rapid weight loss has concluded and your weight has stabilised. Your bariatric team will review your progress at follow-up appointments and advise you on the appropriate time to discontinue treatment.

Dosage Guidance and How to Take Ursodeoxycholic Acid Correctly

The most commonly prescribed dose in the UK is 250 mg twice daily, taken with food to maximise absorption. Always follow your bariatric centre's specific instructions, and space doses at least two hours away from antacids or bile acid sequestrants.

In the UK, ursodeoxycholic acid is available in tablet or capsule form, typically in strengths of 150 mg, 250 mg, or 300 mg. A commonly used prophylactic regimen after gastric sleeve surgery is 250 mg twice daily (500 mg per day), though some centres use doses ranging from 300 mg to 600 mg daily. Some clinical studies have used weight-based dosing of approximately 8–10 mg/kg/day. The specific dose and regimen prescribed to you will reflect your bariatric centre's local protocol; always follow the instructions provided by your surgical team.

To get the most benefit from UDCA, it is important to take it correctly:

• Take with food: UDCA is best absorbed when taken with or after meals, as food stimulates bile flow and enhances the drug's effectiveness

• Consistency matters: Try to take it at the same time(s) each day to maintain steady levels in the body

• Swallow whole: Tablets or capsules should be swallowed with a full glass of water and not crushed or chewed unless your pharmacist confirms this is appropriate for your specific product

• Do not double up: If you miss a dose, take it as soon as you remember — but if it is nearly time for your next dose, skip the missed one and continue as normal

• Spacing around other medicines: Take UDCA at least 2 hours before or 4 hours after cholestyramine, colestipol, or aluminium-containing antacids, as these can significantly reduce UDCA absorption

Following gastric sleeve surgery, your stomach's reduced capacity and altered anatomy can affect how medications are absorbed. Inform your GP and pharmacist that you have had bariatric surgery, as this may influence prescribing decisions for other medications. If you experience difficulty swallowing tablets in the early post-operative period, speak to your surgical team or pharmacist about suitable alternative formulations — some capsule preparations may be opened, depending on the specific product; confirm this with your pharmacist before doing so. Always follow the specific dosage instructions provided by your bariatric centre, as these take precedence over general guidance.

Side Effects and What to Watch For During Treatment

UDCA is generally well tolerated; the most common side effects are diarrhoea, nausea, and mild stomach discomfort. Seek urgent medical attention if you develop severe upper right abdominal pain, jaundice, fever, or dark urine.

Ursodeoxycholic acid is generally well tolerated, and serious adverse effects are uncommon. However, as with any medication, some patients do experience side effects, and it is important to be aware of what to look out for during your course of treatment.

Common side effects include:

• Diarrhoea or loose stools — particularly at higher doses

• Nausea or mild stomach discomfort

• Indigestion or bloating

These gastrointestinal symptoms are usually mild and often improve as your body adjusts to the medication. Taking UDCA with food can help to minimise digestive discomfort. If symptoms persist or become troublesome, contact your GP or bariatric nurse for advice.

Less common but notable effects to be aware of include:

• Skin rash, itching, or hair thinning (alopecia) — if these occur, seek medical advice

• Worsening of liver function in patients with pre-existing liver disease — your team will monitor this if relevant

• In rare cases, calcification of gallstones, which can reduce the effectiveness of the medication

Key contraindications and precautions: UDCA should not be used in patients with acute cholangitis, biliary obstruction, or a non-functioning gallbladder. Your prescriber will have assessed these factors before initiating treatment; inform your team promptly if you develop any new symptoms.

Drug interactions: Several medicines can affect how UDCA works. Cholestyramine, colestipol, and aluminium-containing antacids reduce UDCA absorption (see spacing advice above). Oestrogens and clofibrate may counteract its gallstone-preventing effect. UDCA may increase ciclosporin blood levels (monitoring required) and may reduce the absorption of ciprofloxacin and some calcium-channel blockers such as nitrendipine. Always inform your GP and pharmacist of all medications, supplements, and herbal remedies you are taking.

If you develop symptoms suggestive of gallstone complications — such as severe upper right abdominal pain, jaundice (yellowing of the skin or eyes), fever, or dark urine — seek urgent medical attention, as these may indicate cholecystitis or biliary obstruction regardless of whether you are taking UDCA. The medication reduces risk but does not eliminate it entirely.

Reporting side effects: If you experience a suspected side effect, you can report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Reporting helps improve the safety monitoring of medicines in the UK.

When to Speak to Your Surgical Team About Stopping

Always consult your bariatric team or GP before stopping UDCA, rather than discontinuing independently. Stopping is typically appropriate once your prescribed course is complete and rapid weight loss has concluded.

Deciding when to stop ursodeoxycholic acid should always be a shared decision made in consultation with your bariatric surgical team or GP, rather than something you determine independently. There are several circumstances in which it is particularly important to seek professional guidance before making any changes to your treatment.

You should contact your surgical team or GP if:

• You have completed your prescribed course (typically 6 months) and wish to confirm it is safe to stop

• You are experiencing persistent or worsening side effects that are affecting your quality of life, or if liver function tests become abnormal

• You develop any symptoms of gallbladder disease, such as right-sided abdominal pain after eating, nausea, or vomiting

• Your gallbladder is removed (cholecystectomy) during or after your bariatric journey — UDCA prophylaxis is no longer required once the gallbladder has been removed

• You become pregnant — whilst UDCA is used under specialist supervision for certain liver conditions in pregnancy (such as intrahepatic cholestasis of pregnancy), any decision to continue or stop it during pregnancy requires careful, individualised clinical assessment

• You are prescribed a new medication that may interact with UDCA

Your bariatric follow-up appointments — a standard part of NHS post-operative care — provide an ideal opportunity to review your medication. At these reviews, your team will assess your weight loss trajectory, overall health, and any biliary symptoms before advising on discontinuation.

If your weight loss has plateaued and you are beyond the six-month mark, your team may feel it is appropriate to stop UDCA. Conversely, if you are still losing weight rapidly or have had any biliary symptoms, they may recommend continuing for longer.

Never stop UDCA without advice simply because you feel well — the absence of symptoms does not mean the risk of gallstone formation has passed. Open communication with your surgical team remains the safest approach throughout your post-operative journey.

Frequently Asked Questions